|Bid||16.50 x 1100|
|Ask||16.90 x 2200|
|Day's range||16.49 - 16.75|
|52-week range||15.30 - 20.00|
|Beta (5Y monthly)||1.13|
|PE ratio (TTM)||15.25|
|Forward dividend & yield||0.85 (4.98%)|
|Ex-dividend date||29 Sep 2020|
|1y target est||21.80|
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today at the American Transplant Congress (ATC) 2021 Virtual Connect presented results from a new subgroup analysis of SOT recipients in the Phase 3 TAK-620-303 (SOLSTICE) trial, for the investigational drug TAK-620 (maribavir). More than twice (55.6%, 79/142) as many SOT recipients with R/R CMV infection at baseline treated with maribavir achieved confirmed CMV viremia clearance at Study Week 8 (end of treatment phase) compare
Clinical trials are getting a hard look as the pandemic has shown how the current infrastructure favors inequity.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual’s previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. TIDES enrolled more than 20,000 healthy children and adolescents ages four to 16 years in dengue-endemic countries in Latin America and Asia.